Proteas Health is a biotechnology company delivering integrated quantitative proteomic workflows and a globally patented plasma proteomics platform designed to support drug development, diagnostic translation, and clinical-scale implementation.
Proteas Health delivers quantitative proteomic infrastructure engineered for therapeutic and diagnostic development. The company integrates systems-level proteome characterization, plasma proteomics via the patented BioTAS™ platform, and translational assay development within a unified analytical framework designed for reproducibility, scalability, and regulated laboratory integration.
Designed for disciplined program execution rather than exploratory analysis, our workflows enable mechanistic clarity, systemic drug response evaluation, and progression toward deployable quantitative assays.
To enable mechanism-informed drug development and structured diagnostic translation through reproducible, quantitative proteomic infrastructure engineered for clinical-scale integration.
Proteomic measurement must extend beyond discovery depth to achieve development reliability. Proteas Health engineers workflows with controlled pre-analytical handling, quantitative rigor, and cross-study consistency at the core of platform design.
By integrating standardized plasma stabilization, high-resolution mass spectrometry, and AI-enabled modeling within a unified system, the company enables progression from mechanistic insight to translational assay deployment.
Our approach emphasizes:
Proteas Health’s leadership combines scientific expertise with operational execution to deliver proteomic infrastructure at a development scale.
Founder, President & Chief Technology Officer
Dr. Garbis directs platform innovation and quantitative analytical strategy, bringing decades of experience in proteomics and mass spectrometry across academic, government, and industry settings.
Co-Founder & Chief Scientific Officer
Dr. Manousopoulou oversees scientific execution and translational integration, guiding systems-level proteomic application across development programs.
Chief Operating Officer & Board Member
Mr. Shen leads operational delivery and program integration, ensuring alignment between analytical workflows and development-stage requirements.
Chief Executive Officer & Chairman of the Board
Dr. Nihalani leads corporate strategy and partnerships, aligning Proteas Health’s capabilities with therapeutic and diagnostic development needs.
Director of Bioinformatics
Dr. White leads AI-enabled proteomic modeling and quantitative data integration to generate structured, development-ready outputs.
Proteas Health operates as a U.S.-based biotechnology company with infrastructure designed for regulated program execution, secure data management, and scalable laboratory integration. Workflows support multi-site studies, decentralized collection, and compatibility with CLIA-aligned laboratory environments.